Neurofilament in CSF—A biomarker of disease activity and long-term prognosis in multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Teunissen

Khalil

. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18(5): 552–556.

Trentini

Comabella

Tintore

. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014; 261(12): 2338–2343.

Salzer

Svenningsson

Sundstrom

. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16(3): 287–292.

Kuhle

Disanto

Lorscheider

. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84(16): 1639–1643.

Gunnarsson

Malmeström

Axelsson

. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69(1): 83–89.

Petzold

Steenwijk

Eikelenboom

. Elevated CSF neurofilament proteins predict brain atrophy: A 15 year follow-up study. Mult Scler 2016; 22(9): 1154–1162.

Romme

Ratzer

Bornsen

. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82(17): 1499–1507.

Kuhle

Barro

Disanto

. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. Epub ahead of print 11 January 2016. DOI: 10.1177/1352458515623365.